Circle Cardiovascular Imaging vs Cleerly
This pairing turns on a single architectural fact and a single evidence fact. The architecture: Circle's cvi42 Plaque runs fully on premise, so imaging never leaves the institution, the clearest data residency position in the lane and effectively the only option for buyers under data sovereignty constraints, where Cleerly is a cloud analysis service that sends scans out. The evidence: Cleerly holds an A on clinical evidence with the CREDENCE, PACIFIC, and CONFIRM2 registries and broad Category I reimbursement across a reported 86 million plus covered lives, while no validation study specific to cvi42 Plaque was located, holding Circle at C. The vendors are also different species, Cleerly is an AI plaque company graded A on AI centrality, Circle is an established multi vendor reading platform with a cleared plaque module graded B. If your failure mode is imaging that cannot leave the enterprise, or you already run cvi42, start with Circle. If your failure mode is a proven, broadly reimbursed plaque analysis, start with Cleerly, and establish where your scans are processed.
- The strongest data residency position in the lane: cvi42 Plaque runs fully on premise, so imaging never leaves the institution, graded A on both PHI stewardship and deployment against Cleerly's cloud analysis service, which grades C on deployment.
- Scanner agnostic by heritage: cvi42 is a multi vendor cardiovascular reading platform compatible with all major systems, graded A on interoperability, where Cleerly's specific connectors are not enumerated and it grades C.
- A broader imaging franchise: cvi42 spans cardiac MRI and CT reading rather than a coronary only point solution, with use extending to specialised settings including adult congenital heart disease at Johns Hopkins.
- Coverage breadth today: Cleerly's technology underpins Category I CPT codes, multiple Medicare Administrative Contractor determinations, and commercial payer policies reported at more than 86 million covered lives, an A on regulatory status against Circle's clean but single module B.
- Outcome oriented evidence: the multicenter CREDENCE, PACIFIC, and CONFIRM2 registries, an A on clinical evidence, where no validation study specific to cvi42 Plaque was located and Circle grades C.
- AI is the whole product: Cleerly sells the algorithmic reading itself and grades A on AI centrality, where Circle's franchise is the reading platform and the plaque model is a module on it, graded B on the platform not algorithm principle.
Side-by-Side
| Axis | C Circle Cardiovascular Imaging |
C Cleerly |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
The grades split cleanly by what each vendor is. Cleerly is an AI plaque analysis company, A on AI centrality and clinical evidence, delivered as a cloud service that grades C on deployment. Circle is an established reading platform with a cleared plaque module, so it grades B on AI centrality under this index's platform not algorithm precedent, and C on clinical evidence because no validation study specific to cvi42 Plaque was located, category level endorsement not being product level evidence. Circle's countervailing strength is architectural: A on PHI stewardship and deployment for fully on premise analysis, and A on interoperability for multi vendor compatibility. The Category III to Category I transition both vendors describe is set by the payer system. Neither publishes a licence price or, in Cleerly's case, data residency terms; Circle's on premise model resolves residency structurally.